These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1717600)

  • 1. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
    Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
    J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain.
    Ghetie V; Ghetie MA; Uhr JW; Vitetta ES
    J Immunol Methods; 1988 Sep; 112(2):267-77. PubMed ID: 3262139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
    Ghetie V; Swindell E; Uhr JW; Vitetta ES
    J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain.
    Ghetie V; Till MA; Ghetie MA; Uhr JW; Vitetta ES
    J Immunol Methods; 1990 Jan; 126(1):135-41. PubMed ID: 2303721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
    Mansfield E; Amlot P; Pastan I; FitzGerald DJ
    Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
    Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
    Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
    Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
    Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
    Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
    Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
    Pop LM; Liu X; Ghetie V; Vitetta ES
    Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.